In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

doi:10.1084/jem.179.4.1215

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Levitsky, H. I.
	Articles by Pardoll, D. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Levitsky, H. I.
	Articles by Pardoll, D. M.


Social Bookmarking

	What's this?

ARTICLES

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

HI Levitsky, A Lazenby, RJ Hayashi and DM Pardoll
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Downregulation of major histocompatibility complex (MHC) class I expression is an important mechanism by which tumors evade classical T cell-dependent immune responses. Therefore, a system was designed to evaluate parameters for active immunization against MHC class I- tumors. Mice were capable of rejecting a MHC class I- tumor challenge after immunization with an irradiated granulocyte/macrophage colony- stimulating factor (GM-CSF) transduced MHC class I- tumor vaccine. This response was critically dependent on CD4+ T cells and natural killer (NK) cells, but minimally on CD8+ T cells. A strong protective response against MHC class I+ variants of the tumor could be elicited when mice were immunized with irradiated MHC class I+ GM-CSF-secreting tumor cells. This response required CD4+ and CD8+ T cells, and in addition, elimination of NK cells resulted in outgrowth of tumors that had lost expression of at least one MHC class I gene. Finally, class I MHC expression on the vaccinating cells inhibited the response generated against a MHC class I- tumor challenge. These results demonstrate that the host is capable of being immunized against a tumor that has lost MHC class I expression and reveal conditions under which distinct effector cells play a role in the systemic antitumor immune response.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., Gattinoni, L., Wrzesinski, C., Hinrichs, C. S., Kerstann, K. W., Feigenbaum, L., Chan, C.-C., Restifo, N. P. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373 [Abstract] [Full Text]
Saha, A., Chatterjee, S. K., Foon, K. A., Celis, E., Bhattacharya-Chatterjee, M. (2007). Therapy of Established Tumors in a Novel Murine Model Transgenic for Human Carcinoembryonic Antigen and HLA-A2 with a Combination of Anti-idiotype Vaccine and CTL Peptides of Carcinoembryonic Antigen. Cancer Res. 67: 2881-2892 [Abstract] [Full Text]
Perri, S. R., Martineau, D., Francois, M., Lejeune, L., Bisson, L., Durocher, Y., Galipeau, J. (2007). Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Molecular Cancer Therapeutics 6: 441-449 [Abstract] [Full Text]
Charalambous, A., Oks, M., Nchinda, G., Yamazaki, S., Steinman, R. M. (2006). Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin. J. Immunol. 177: 8410-8421 [Abstract] [Full Text]
Chiang, E. Y., Stroynowski, I. (2006). The Role of Structurally Conserved Class I MHC in Tumor Rejection: Contribution of the Q8 Locus. J. Immunol. 177: 2123-2130 [Abstract] [Full Text]
Maksimow, M., Miiluniemi, M., Marttila-Ichihara, F., Jalkanen, S., Hanninen, A. (2006). Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 108: 1298-1305 [Abstract] [Full Text]
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., Lackner, A., Alvarez, X., Ochoa, A., Chen, L., Zou, W. (2006). B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881 [Abstract] [Full Text]
Errington, F., Bateman, A., Kottke, T., Thompson, J., Harrington, K., Merrick, A., Hatfield, P., Selby, P., Vile, R., Melcher, A. (2006). Allogeneic Tumor Cells Expressing Fusogenic Membrane Glycoproteins as a Platform for Clinical Cancer Immunotherapy. Clin. Cancer Res. 12: 1333-1341 [Abstract] [Full Text]
Hokey, D. A., Larregina, A. T., Erdos, G., Watkins, S. C., Falo, L. D. Jr. (2005). Tumor Cell Loaded Type-1 Polarized Dendritic Cells Induce Th1-Mediated Tumor Immunity. Cancer Res. 65: 10059-10067 [Abstract] [Full Text]
van Houdt, I. S., Oudejans, J. J., van den Eertwegh, A. J.M., Baars, A., Vos, W., Bladergroen, B. A., Rimoldi, D., Muris, J. J.F., Hooijberg, E., Gundy, C. M., Meijer, C. J.L.M., Kummer, J. A. (2005). Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma. Clin. Cancer Res. 11: 6400-6407 [Abstract] [Full Text]
Park, J. M., Terabe, M., Sakai, Y., Munasinghe, J., Forni, G., Morris, J. C., Berzofsky, J. A. (2005). Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas. J. Immunol. 174: 4228-4236 [Abstract] [Full Text]
Zhao, Y., Boczkowski, D., Nair, S. K., Gilboa, E. (2003). Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 102: 4137-4142 [Abstract] [Full Text]
Flynn, S., Stockinger, B. (2003). Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood 101: 4472-4478 [Abstract] [Full Text]
Esplugues, E., Sancho, D., Vega-Ramos, J., Martinez-A, C., Syrbe, U., Hamann, A., Engel, P., Sanchez-Madrid, F., Lauzurica, P. (2003). Enhanced Antitumor Immunity in Mice Deficient in CD69. J. Exp. Med. 197: 1093-1106 [Abstract] [Full Text]
Chiang, E. Y., Henson, M., Stroynowski, I. (2003). Correction of Defects Responsible for Impaired Qa-2 Class Ib MHC Expression on Melanoma Cells Protects Mice from Tumor Growth. J. Immunol. 170: 4515-4523 [Abstract] [Full Text]
Curti, A., Parenza, M., Colombo, M. P. (2003). Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 101: 568-575 [Abstract] [Full Text]
Yu, B., Kusmartsev, S., Cheng, F., Paolini, M., Nefedova, Y., Sotomayor, E., Gabrilovich, D. (2003). Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer. Clin. Cancer Res. 9: 285-294 [Abstract] [Full Text]
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., Storkus, W. J. (2002). Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma. J. Exp. Med. 196: 619-628 [Abstract] [Full Text]
Chiang, E. Y., Henson, M., Stroynowski, I. (2002). The Nonclassical Major Histocompatibility Complex Molecule Qa-2 Protects Tumor Cells from NK Cell- and Lymphokine-Activated Killer Cell-Mediated Cytolysis. J. Immunol. 168: 2200-2211 [Abstract] [Full Text]
Teshima, T., Liu, C., Lowler, K. P., Dranoff, G., Ferrara, J. L. M. (2002). Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation. Cancer Res. 62: 796-800 [Abstract] [Full Text]
Segal, B. M., Glass, D. D., Shevach, E. M. (2002). Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection. J. Immunol. 168: 1-4 [Abstract] [Full Text]
Beatty, G. L., Paterson, Y. (2001). IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}}. J. Immunol. 166: 2276-2282 [Abstract] [Full Text]
Teshima, T., Mach, N., Hill, G. R., Pan, L., Gillessen, S., Dranoff, G., Ferrara, J. L. M. (2001). Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation. Cancer Res. 61: 162-171 [Abstract] [Full Text]
Kedl, R. M., Rees, W. A., Hildeman, D. A., Schaefer, B., Mitchell, T., Kappler, J., Marrack, P. (2000). T Cells Compete for Access to Antigen-bearing Antigen-presenting Cells. J. Exp. Med. 192: 1105-1114 [Abstract] [Full Text]
Lanuti, M., Rudginsky, S., Force, S. D., Lambright, E. S., Siders, W. M., Chang, M. Y., Amin, K. M., Kaiser, L. R., Scheule, R. K., Albelda, S. M. (2000). Cationic Lipid:Bacterial DNA Complexes Elicit Adaptive Cellular Immunity in Murine Intraperitoneal Tumor Models. Cancer Res. 60: 2955-2963 [Abstract] [Full Text]
Salvadori, S., Martinelli, G., Zier, K. (2000). Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity. J. Immunol. 164: 2214-2220 [Abstract] [Full Text]
van Elsas, A., Hurwitz, A. A., Allison, J. P. (1999). Combination Immunotherapy of B16 Melanoma Using Anti�Cytotoxic T Lymphocyte�associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. J. Exp. Med. 190: 355-366 [Abstract] [Full Text]
Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., Vile, R. G. (1999). Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake. J. Immunol. 163: 1398-1408 [Abstract] [Full Text]
Fujii, S.-i., Hamada, H., Fujimoto, K., Shimomura, T., Kawakita, M. (1999). Activated Dendritic Cells From Bone Marrow Cells of Mice Receiving Cytokine-Expressing Tumor Cells Are Associated With the Enhanced Survival of Mice Bearing Syngeneic Tumors. Blood 93: 4328-4335 [Abstract] [Full Text]
Imro, M. A., Manici, S., Russo, V., Consogno, G., Bellone, M., Rugarli, C., Traversari, C., Protti, M. P. (1999). Major Histocompatibility Complex Class I Restricted Cytotoxic T Cells Specific for Natural Melanoma Peptides Recognize Unidentified Shared Melanoma Antigen(s). Cancer Res. 59: 2287-2291 [Abstract] [Full Text]
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H. (1998). The Central Role of CD4+ T Cells in the Antitumor Immune Response. J. Exp. Med. 188: 2357-2368 [Abstract] [Full Text]
TODRYK, S M, CHONG, H, VILE, R G, PANDHA, H, LEMOINE, N R (1998). Can immunotherapy by gene transfer tip the balance against colorectal cancer?. Gut 43: 445-449 [Abstract] [Full Text]
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., Allison, J. P. (1998). CTLA-4 blockade synergizes with tumor-derived granulocyte- macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95: 10067-10071 [Abstract] [Full Text]
Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., Allison, J. P. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate�cancer. Proc. Natl. Acad. Sci. USA 94: 8099-8103 [Abstract] [Full Text]
Mey-Tal, S. V., Schechter, C., Ehrlich, R. (1997). Synthesis and Turnover of beta 2-Microglobulin in Ad12-transformed Cells Defective in Assembly and Transport of Class I Major Histocompatibility Complex Molecules. J. Biol. Chem. 272: 353-361 [Abstract] [Full Text]
Huang, A., Golumbek, P, Ahmadzadeh, M, Jaffee, E, Pardoll, D, Levitsky, H (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965 [Abstract]